CRISPR-Cas9 gene editing was used to modify the coding region of the MAP3K6 mouse gene. The genetic modification resulted in the deletion of the full length production of the protein. This modification was made in a C57BL/6J genetic background. MAP3K6 is a signaling molecule and could be the target of future host-directed therapies to treat diseases.